Is the "Common Cold" Our Greatest Ally in the Battle Against SARS-CoV-2?

被引:4
|
作者
Capoor, Manu N. [1 ,2 ]
Ahmed, Fahad S. [3 ]
McDowell, Andrew [4 ]
Slaby, Ondrej [5 ,6 ]
机构
[1] Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, 1230 York Ave, New York, NY 10021 USA
[2] MMF Syst Inc, Execut Off, New York, NY 10022 USA
[3] MyMedicalFiles MMF Syst Inc, Data Sci & Engn, New York, NY USA
[4] Ulster Univ, Sch Biomed Sci, Nutr Innovat Ctr Food & Hlth NICHE, Coleraine, Londonderry, North Ireland
[5] Masaryk Univ, Cent European Inst Technol CEITEC, Brno, Czech Republic
[6] Masaryk Univ, Dept Biol, Fac Med, Brno, Czech Republic
关键词
SARS-CoV-2; COVID-19; T-cell; human coronaviruses; immunity; contact tracing; children; COVID-19; CHILDREN;
D O I
10.3389/fcimb.2020.605334
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The discovery of T-cell responses to SARS-CoV-2 in non-infected individuals indicates cross-reactive immune memory from prior exposure to human coronaviruses (HCoV) that cause the common cold. This raises the possibility that "immunity" could exist within populations at rates that may be higher than serology studies estimate. Besides specialized research labs, however, there is limited ability to measure HCoV CD4+ and CD8+ T-cell responses to SARS-CoV-2 infection, which currently impedes interpretation of any potential correlation between COVID-19 disease pathogenesis and the calibration of pandemic control measures. Given this limited testing ability, an alternative approach would be to exploit the large cohort of currently available data from which statistically significant associations may be generated. This would necessitate the merging of several public databases including patient and contact tracing, which could be created by relevant public health organizations. Including data from both symptomatic and asymptomatic patients in SARS-CoV-2 databases and surveillance systems could provide the necessary information to allow for more informed decisions.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Phytochemicals Against SARS-COV-2 Infection
    Agrawal, Pawan K. K.
    Blunden, Gerald
    NATURAL PRODUCT COMMUNICATIONS, 2023, 18 (02)
  • [32] Disinfectants against SARS-CoV-2: A Review
    Xiao, Shuqi
    Yuan, Zhiming
    Huang, Yi
    VIRUSES-BASEL, 2022, 14 (08):
  • [33] Development of vaccines against SARS-CoV-2
    Leon-Lara, Ximena
    Otero-Mendoza, Francisco
    ACTA PEDIATRICA DE MEXICO, 2020, 41 (04): : S23 - S26
  • [34] Therapeutic nanobodies against SARS-CoV-2
    Güttler T.
    Dobbelstein M.
    Görlich D.
    BIOspektrum, 2022, 28 (1) : 39 - 42
  • [35] Antivirals against SARS-CoV-2 by autumn?
    Smith, David
    Gill, Dipender
    BMJ-BRITISH MEDICAL JOURNAL, 2021, 373
  • [36] Vaccinating children against SARS-CoV-2
    Lavine, Jennie S.
    Bjornstad, Ottar
    Antia, Rustom
    BMJ-BRITISH MEDICAL JOURNAL, 2021, 373
  • [37] SARS-COV-2 infection in a patient with Evans syndrome: a silent enemy or an ally?
    Pantic, Nikola
    Mitrovic, Mirjana
    Virijevic, Marijana
    Sabljic, Nikica
    Pravdic, Zlatko
    Suvajdzic, Nada
    VOJNOSANITETSKI PREGLED, 2020, 77 (12) : 1348 - 1350
  • [38] Vaccinations against SARS-CoV-2 and the Skin
    Mockenhaupt, Maja
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 (03): : 223 - 224
  • [39] Timing vaccination against SARS-CoV-2
    Coline Barnoud
    Chen Wang
    Christoph Scheiermann
    Cell Research, 2021, 31 : 1146 - 1147
  • [40] Investigating hypothiocyanite against SARS-CoV-2
    Cegolon, L.
    INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH, 2020, 227